Rinfabate

Drug Profile

Rinfabate

Alternative Names: Recombinant human insulin-like growth factor-binding protein-3; rhIGFBP-3

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Insmed
  • Class Antineoplastics; Proteins
  • Mechanism of Action Growth modulators; Insulin-like growth factor I modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 27 Jul 2017 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 09 Nov 2010 No development reported - Phase-I for Solid tumours in USA (IV)
  • 02 Apr 2008 This compound is still available for licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top